| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having excellent apoptosis inhibiting actions by including troglitazone as an active ingredient. SOLUTION: This inhibitor is obtained by including troglitazone or its pharmacologically acceptable salt (e.g. a sodium salt, a calcium salt or an ammonium salt) as an active ingredient. The daily dose of the active ingredient is preferably 0.1-1,000 mg at a time in the case of oral administration and 0.01-500 mg at a time in the case of intravenous administration. The above inhibitor is useful for diseases in the nervous system, e.g. ischemic disorders (e.g. cerebral apoplexy, cerebral hemorrhage or cerebral infarction), inflammatory diseases (e.g. sequelae of encephalitis, acute diffuse cerebromeningitis or bacterial cerebromeningitis) or neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease or Down's syndrome).
|
